<DOC>
	<DOCNO>NCT02054481</DOCNO>
	<brief_summary>The overall purpose trial ass clinical efficacy safety different subcutaneous dos BI 655066 adult patient chronic plaque psoriasis order select dose clinical trial .</brief_summary>
	<brief_title>BI 655066 Dose Ranging Psoriasis , Active Comparator Ustekinumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Inclusion criterion : Body Mass Index ( BMI ) &gt; /= 18.5 &lt; 40 kg/m² Patients stable moderate severe chronic plaquetype psoriasis without psoriatic arthritis involve &gt; /= 10 % body surface area , disease severity PASI &gt; /= 12 sPGA score moderate ( score least 3 ) screen visit visit 2 ( randomisation ) , assess investigator Psoriasis disease duration least 6 month prior screen , assessed investigator Patients must candidate systemic psoriasis treatment phototherapy , assess investigator Patients must suitable candidate ustekinumab ( Stelara® ) therapy give local label Patient must give informed consent sign approve consent form prior study procedure accordance GCP local legislation Exclusion criterion : Patients guttate , erythrodermic , pustular psoriasis patient druginduced psoriasis , diagnose investigator Evidence current previous clinically significant disease , medical condition psoriasis , find medical examination ( include vital sign ECG ) , opinion investigator , would compromise safety patient quality data . This criterion provide opportunity investigator exclude patient base clinical judgment , even eligibility criterion satisfy . ( Psoriatic arthritis consider exclusion criterion ) Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder , history orthostatic hypotension , faint spell blackout , investigator 's judgement , could jeopardize safe conduct study . Clinically important acute chronic infection include hepatitis HIV . With regard tuberculosis follow applies : Have sign symptom suggestive current active latent TB upon medical history , physical examination and/or chest radiograph ( posterioranterior lateral view , take within 3 month prior first administration study drug read qualified radiologist ) . Have history latent active TB prior screen , except patient documentation complete adequate treatment regimen least 6 month prior first administration study agent . Have positive IGRA testing ( QuantiFERONTB Gold ) within 2 month prior screen , active TB rule , except patient history latent TB documentation complete adequate treatment regimen least 6 month prior first administration study agent . Have live vaccination &lt; /= 12 week prior randomisation ( visit 2 ) . Patients must agree receive live vaccination study . No BCG vaccine give one year prior randomisation ( visit 2 ) , study one year last administration study drug ( accord Stelara® SPC ) . History clinically significant hypersensitivity systemically administer biologic agent excipients History malignancy past 5 year suspicion active malignant disease except treat cutaneous squamous cell basal cell carcinoma Has receive therapeutic agent directly target IL12 , IL23 ( include ustekinumab ( Stelara® ) ) Use biologic agent within 12 week ( infliximab , etanercept , adalimumab , biologics ) prior treatment , systemic antipsoriatic medication phototherapy within 4 week prior treatment , topical antipsoriasis medication within 2 week prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>